Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRIATIC: durvalumab with or without tremelimumab versus placebo after concurrent chemoradiotherapy in limited-stage small-cell lung cancer
2023-509602-29-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of durvalumab and tiragolumab in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Feb 2019; status: completed.
02
Drugs
durvalumabtiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-509602-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509602-29-00.